Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
BCT Stock Chart & Stats
C$10.64
-C$0.02(-3.08%)
At close: 4:00 PM EST
C$10.64
-C$0.02(-3.08%)
Day’s Range― - ―
52-Week RangeC$5.13 - C$135.00
Previous CloseN/A
Volume105.15K
Average Volume (3M)3.11K
Market Cap
C$39.88M
Enterprise ValueC$4.75M
Total Cash (Recent Filing)C$10.18M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.04
Shares Outstanding7,250,487
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 DSMB SupportRepeated positive DSMB reviews reduce the probability of trial suspension and indicate an ongoing acceptable safety profile for Bria-IMT in the pivotal Bria-ABC study. That structural continuity preserves the pathway to pivotal efficacy readouts and potential regulatory filings, which materially affects long-term commercial prospects.
FDA Fast Track DesignationFast Track status is a durable regulatory advantage: it enables more frequent FDA interaction, potential rolling review, and expedited development. For a clinical-stage oncology company, this materially shortens time-to-market if efficacy is shown, improving strategic optionality and partner interest over the medium term.
Low Financial Leverage (zero Debt)Zero reported debt lowers near-term solvency risk and preserves flexibility for restructurings, partnerships, or future financing terms. For a cash-burning biotech, low leverage reduces fixed financing obligations and bankruptcy risk, providing a structural cushion while development milestones are pursued.
Bears Say
Pre-revenue StatusNo product revenue means the company’s long-term viability hinges entirely on clinical success or external funding. Without commercial cash flow, operational runway and strategic independence depend on milestone outcomes and financing events, increasing structural execution and dilution risk over the next several quarters.
High And Persistent Cash BurnLarge negative operating and free cash flows indicate ongoing funding needs and elevated dilution risk. Persistent burn constrains the company’s ability to expand trials or invest in parallel programs, forcing prioritization or partnerships and creating structural dependence on capital markets or collaborators.
Shrinking Equity And Modest AssetsSubstantial declines in shareholders' equity and a small asset base reflect accumulated losses and prior dilution, limiting the balance sheet buffer. That structural weakness reduces negotiation leverage with partners and financiers and heightens vulnerability to adverse funding conditions or trial setbacks.
BriaCell Therapeutics News
BCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$5.13 and its highest was C$135.00 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$39.88M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Mar 18, 2026 which is in 27 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Dec 11, 2025. The company reported -C$6.038 earnings per share for the quarter, missing the consensus estimate of N/A by -C$6.038.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 7,250,487 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -C$6.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.816%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―